# ASP-II: Ancrod Stroke Program: Ancrod (Viprinex™) for the Treatment of Acute, Ischemic Stroke

> **NCT00300196** · PHASE3 · TERMINATED · sponsor: **Neurobiological Technologies** · enrollment: 311 (actual)

## Conditions studied

- Stroke
- Cerebral Ischemia
- Brain Infarction

## Interventions

- **BIOLOGICAL:** Ancrod (Viprinex)
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT00300196
- **Lead sponsor:** Neurobiological Technologies
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2006-03
- **Primary completion:** 2008-12
- **Final completion:** 2008-12
- **Target enrollment:** 311 (ACTUAL)
- **Why stopped:** Futility
- **Last updated:** 2010-01-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00300196

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00300196, "ASP-II: Ancrod Stroke Program: Ancrod (Viprinex™) for the Treatment of Acute, Ischemic Stroke". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT00300196. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*